Axogen 8-K: Financials & Officer Comp Updates on Jan 4, 2024

Ticker: AXGN · Form: 8-K · Filed: Jan 4, 2024 · CIK: 805928

Axogen, Inc. 8-K Filing Summary
FieldDetail
CompanyAxogen, Inc. (AXGN)
Form Type8-K
Filed DateJan 4, 2024
Risk Levellow
Pages5
Reading Time6 min
Key Dollar Amounts$0.01, $112,500, $75,000
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, executive-compensation, corporate-governance

TL;DR

**Axogen just dropped an 8-K on Jan 4, 2024, detailing financial results and officer pay changes.**

AI Summary

Axogen, Inc. filed an 8-K on January 4, 2024, reporting on its results of operations and financial condition, as well as changes in its executive compensation arrangements. This filing indicates that the company is providing an update on its financial performance and potentially adjusting how it compensates its key officers. For investors, this matters because it offers a glimpse into the company's recent financial health and how it's managing executive incentives, which can influence future performance and shareholder value.

Why It Matters

This filing provides investors with current information on Axogen's financial health and executive compensation, which are key indicators of company stability and future strategic direction.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial and operational updates, not indicating any immediate high-risk events.

Analyst Insight

A smart investor would monitor Axogen's upcoming detailed financial reports and any subsequent announcements regarding executive compensation or leadership changes to understand their potential impact on the company's strategic direction and financial health.

Key Numbers

  • January 4, 2024 — Date of Report (The earliest event reported in this filing occurred on this date.)
  • 001-36046 — Commission File Number (Identifies Axogen, Inc.'s specific filing record with the SEC.)
  • 41-1301878 — I.R.S. Employer Identification No. (Unique tax identification number for Axogen, Inc.)
  • 3845 — Standard Industrial Classification (SIC) (Categorizes Axogen, Inc. as 'ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS'.)
  • 1231 — Fiscal Year End (Indicates Axogen, Inc.'s fiscal year ends on December 31st.)

Key Players & Entities

  • Axogen, Inc. (company) — the registrant filing the 8-K
  • January 4, 2024 (date) — date of earliest event reported and filing date
  • Minnesota (company) — state of incorporation for Axogen, Inc.
  • 001-36046 (dollar_amount) — Commission File Number
  • 41-1301878 (dollar_amount) — I.R.S. Employer Identification No.
  • 13631 Progress Boulevard, Suite 400 Alachua, Florida 32615 (company) — principal executive offices address
  • (386) 462-6800 (dollar_amount) — Registrant's telephone number
  • AXGN (company) — trading symbol for Common Stock

Forward-Looking Statements

  • Axogen will provide more detailed financial results in an upcoming earnings report. (Axogen, Inc.) — high confidence, target: Q1 2024 earnings call
  • Changes in officer compensation could lead to shifts in executive leadership or strategy. (Axogen, Inc. officers) — medium confidence, target: Mid-2024

FAQ

What is the primary purpose of Axogen, Inc.'s 8-K filing dated January 4, 2024?

The primary purpose of Axogen, Inc.'s 8-K filing dated January 4, 2024, is to report on its results of operations and financial condition, as well as to disclose information regarding the departure or election of directors or certain officers and compensatory arrangements of certain officers, as per Item Information sections.

What is Axogen, Inc.'s trading symbol and on which exchange is its common stock registered?

Axogen, Inc.'s trading symbol is AXGN, and its Common Stock, with a $0.01 par value, is registered on The Nasdaq Stock Market (implied by 'The N' in the filing, typically Nasdaq).

What is the state of incorporation for Axogen, Inc.?

Axogen, Inc. is incorporated in Minnesota, as stated in the 'State or Other Jurisdiction of Incorporation or Organization' section of the filing.

What is the business address of Axogen, Inc. as listed in the filing?

The business address of Axogen, Inc. is 13631 Progress Boulevard, Suite 400, Alachua, Florida 32615, with a telephone number of (386) 462-6800.

Under which SEC Act is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as indicated in the 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' header.

Filing Stats: 1,420 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2024-01-04 16:56:02

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market
  • $112,500 — ed as a senior advisor and will receive $112,500 per month for the first six months for
  • $75,000 — onths for 40 hours of work per week and $75,000 per month for the final three months fo

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 4, 2024, Axogen, Inc. (the "Company") issued a press release announcing its preliminary, unaudited fourth quarter and full year 2023 financial performance. A copy of the press release is furnished as Exhibit 99.1. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Directors. Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the "CEO") and President of the Company informed the Company of her intention to retire in January 2025. The Company's Board of Directors (the "Board") will engage an executive recruitment firm and initiate the process for a new CEO search. When a new CEO is in place, Ms. Zadarej will step down from her executive post and Board duties and continue as a consultant to Axogen through the leadership transition. Pursuant to the terms of the Transition and Separation Agreement, dated January 4, 2024, between the Company and Ms. Zaderej (the "Transition Agreement"), Ms. Zaderej will remain the Company's CEO until the earlier of (i) January 4, 2025, (ii) the date the Board identifies a new CEO, or (iii) she is terminated with or without substantial cause (the "CEO Term"). During the CEO Term, Ms. Zaderej will continue to receive her base salary and benefits,

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 4, 2024, the Company issued a press release announcing the retirement of Ms. Zaderej. A copy of this press release is furnished as Exhibit 99.2. The information in this Item 7.01, including Exhibit 99.2 and Exhibit 99.3, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits See the Exhibit index below, which is incorporated herein by reference. Exhibit No. Description 10.1 Transition and Separation Agreement, dated January 4, 2024, between the Company and Karen Zaderej 99.1 Axogen Inc. Press Release dated January 4, 2024, regarding Preliminary 2023 Financial Results 99.2 Axogen Inc. Press Release dated January 4, 2024, regarding Karen Zaderej's Retirement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: January 4, 2024 By: Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.